

Bangalore, India, October 27,2010

Q3 FY10 Press Release

STRONG PERFORMANCE ACROSS BUSINESS DIVISIONS STEERS 35% GROWTH IN REVENUE FOR STRIDES

• EBIDTA Growth Ahead of Guidance

Strides Arcolab Limited (BSE: 532531, NSE: STAR) today announced its unaudited consolidated financial results for the quarter ended September 30, 2010:

Highlights


- Growth in line with guidance
- Australasia Business continues to deliver superior performance
- · Specialties Business continues to record strong growth
- Thrust on global filings and approvals continue
- 50th ANDA approval received this quarter
- 16 filings in EU YTD 2010

Consolidated Financial Highlights for the Quarter ended Sept '10

- Revenues at Rs 4,304 Mn, 35% Growth (Rs 3,191 Mn in Q309)
- EBITDA at Rs 884 Mn, **108% Growth (**Rs 426 Mn in Q309)
- PBT at Rs 518 Mn, 203% Growth over (Rs 171 Mn in Q309)
- PAT (Before Minority) at Rs 407 Mn, 85% Growth (Rs 220 Mn in Q309)
- Accretion in EPS by 60% over Q309

Consolidated Financial Highlights for YTD September, FY10

- Revenues at Rs 12,957 Mn, 40% Growth (Rs 9,244 Mn in YTD Q309)
- EBITDA at Rs 3048 Mn, 140% Growth (Rs 1,267 Mn in YTD Q309
- PBT at Rs 1,607 Mn, 103% Growth (Rs 793 Mn in YTD Q309)
- PAT (Before Minority) at Rs 1,338 Mn, 74% Growth (Rs 767 Mn in YTD Q309
- Accretion in EPS by 57% over YTD Q309



Business-Wise Performance during the quarter

Rs in Million

	Revenues				EBITDA			
Business	Q3′2010	%	Q3′2009	Growth %	Q3′2010	%	Q3′2009	Growth %
Specialties	1,265	29%	814	55%	354	40%	234	100+%
Pharma	3,039	71%	2,377	28%	530	60%	192	100+%
Total	4,304*		3,191	35%	884		426	100+%

^{*}Includes licensing income of Rs 472 million

Business-Wise Performance - YTD Sept '10

Rs in Million


	Revenues				EBITDA			
Business	YTD 2010	%	YTD 2009	Growth %	YTD 2010	%	YTD 2009	Growth %
Specialties	4,699	36%	2,518	87%	1,861	61%	639	100+%
Pharma	8,258	64%	6,726	22%	1,187	39%	628	89%
Total	12,957*		9,244	40%	3,048		1,267	100+%

^{*}Includes licensing income of Rs 2,647 million

Stand-alone Financial Q3, FY10

Performance Indicator	Q3,FY10	Q3,FY09	Growth	
Revenues	1,359	1,239	10%	
EBITDA	207	39	100+%	
PAT	107	(146)	100+%	

Commenting on the quarter performance, Mr. Arun Kumar, Group CEO, said, "We are pleased to report a solid performance with EBIDTA growth ahead of guidance supported by strong performance across all business divisions. The continued momentum in global regulatory filings and approvals is encouraging."



Filings and Approvals – Regulated Markets

Territory	Filings*	Approvals
USA	140	51
Europe	36	6
Australia	23	12
South Africa	96	29
Canada	7	5
New Zealand	2	2
WHO	18	9

^{* 104} filings in Steriles in the USA, 16 Filings in Steriles in Europe

Other Highlight

Successfully completed a QIP worth Rs. 4,550 Million

Strides Arcolab Limited: Leadership through Partnering

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables. The Company has 14 manufacturing facilities across 6 countries and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	PR Consultancy
Mr. T.S. Rangan, Group CFO	
+91 80 66580115	Mahesh Nair, Corporate Voice/Weber Shandwick +91 9880376648
Mr. Kannan. N (Investors) +91 98450 54745	maheshn@corvoshandwick.co.in
	Kasturi Wasmatkar
Melissa Arulappan (Media)	+91 9916728393
+91 98450 22389	kasturi@corvoshandwick.co.in

